News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • US equity futures flat with light volume and no major catalysts in the hour.
  • Treasury yields little changed after no new economic data or Fed comments.
  • Dollar steady versus major currencies amid an absence of macro releases.
  • Oil prices muted as supply data and OPEC commentary remain limited.
  • No major geopolitical developments reported, keeping risk sentiment unchanged.
  • Corporate calendar sparse with no significant earnings or M&A announcements this hour.

Latest Articles

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Priovant Therapeutics, a Roivant company, reported positive Phase 3 trial results for brepocitinib in dermatomyositis, showing statistically significant improvements over placebo in multiple efficacy endpoints including muscle strength, skin disease, physical function, and corticosteroid reduction. Results were published in the New England Journal …

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Biogen announced positive Phase 2 results from the AMETHYST study for litifilimab, an investigational monoclonal antibody targeting BDCA2, demonstrating statistically significant improvement in skin disease activity in patients with cutaneous lupus erythematosus (CLE). These consistent positive results, along with a favorable safety profile and FDA…

Major AMREP Shareholder Adds to Stake with $105,210 Purchase

Major AMREP Shareholder Adds to Stake with $105,210 Purchase

James H. Dahl, listed as a 10% owner of AMREP CORP (NASDAQ: AXR), bought 4,000 shares on March 26, 2026, spending $105,210 across multiple trades executed between $25.4356 and $27.164 per share. The purchases raise his direct stake to 474,398 shares while he also holds additional shares indirectly through IRAs and a trust. The stock has returned 38…

Marvell Data Center President Sells $4.42M in Stock as Company Rolls Out New PCIe 6.0 Switch and Confirms Dividend

Marvell Data Center President Sells $4.42M in Stock as Company Rolls Out New PCIe 6.0 Switch and Confirms Dividend

Sandeep Bharathi, president of Marvell Technology's Data Center Group, sold 44,414 shares on March 26, 2026, for about $4.42 million under a 10b5-1 plan. The transaction came as Marvell introduced the Structera S 60260 PCIe 6.0 switch, declared a quarterly dividend, and retained Buy ratings from Stifel and UBS amid its partnerships and revenue targ…

Protagonist Therapeutics CFO Sells $2.58M in Shares After Option Exercises; FDA Approval Spurs Analyst Upgrades

Protagonist Therapeutics CFO Sells $2.58M in Shares After Option Exercises; FDA Approval Spurs Analyst Upgrades

Protagonist Therapeutics' Chief Financial Officer, Ali Asif, sold 24,765 shares of the company's common stock on March 26, 2026, for roughly $2.58 million at $104.24 per share. On the same day he exercised options to acquire an identical number of shares across two grants. The company recently received FDA approval for its psoriasis treatment Icoty…

Protagonist CMO Sells $1.57M in Stock After Option Exercise as Icotyde Approval Spurs Analyst Upgrades

Protagonist CMO Sells $1.57M in Stock After Option Exercise as Icotyde Approval Spurs Analyst Upgrades

Arturo Molina, M.D., the chief medical officer of Protagonist Therapeutics (PTGX), sold 15,000 shares of common stock on March 26, 2026, generating about $1.57 million. Molina also exercised options to acquire 15,000 shares at $8.04. The trades come as Protagonist shares have climbed sharply following FDA approval of Icotyde (icotrokinra), promptin…

Bank of America to pay $72.5 million to resolve Epstein-related lawsuit

Bank of America to pay $72.5 million to resolve Epstein-related lawsuit

Bank of America has agreed to a $72.5 million settlement to resolve a civil suit brought by women who say the bank facilitated their sexual abuse by Jeffrey Epstein, according to court records. The agreement, which requires approval from U.S. District Judge Jed Rakoff, settles claims that the bank ignored suspicious financial activity tied to Epste…

Political Standoff Over ICE Funding Produces Few Concrete Wins for Either Party

Political Standoff Over ICE Funding Produces Few Concrete Wins for Either Party

A partisan impasse over funding and policy restrictions for U.S. Immigration and Customs Enforcement has left both parties claiming partial victories while producing limited legislative change. Democrats used negotiations to spotlight aggressive ICE tactics and to signal electoral priorities, but most of their proposed curbs failed to win Republica…

Trump Says U.S. 'Does Not Have to Be There' for NATO After European Non-Support

Trump Says U.S. 'Does Not Have to Be There' for NATO After European Non-Support

Speaking at an investment forum in Miami, President Donald Trump said the United States "does not have to be there for NATO," criticizing European allies for declining to provide material support as the U.S. enters the fourth week of its war on Iran. He said the lack of support undercuts U.S. obligations, and his remarks revive longstanding questio…

Indie Semiconductor CEO Executes $153K Sale Under 10b5-1 Plan as Company Advances Product and Financing Plans

Indie Semiconductor CEO Executes $153K Sale Under 10b5-1 Plan as Company Advances Product and Financing Plans

Indie Semiconductor Chief Executive Officer Donald McClymont sold 50,000 shares of Class A common stock on March 25, 2026, for about $153,110 under a Rule 10b5-1 trading plan. The company concurrently disclosed a product milestone in ultraviolet laser diodes for quantum computing, planned convertible note offerings due 2031, and a new in-cabin moni…

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

Fusion Fuel Green PLC announced details on its anticipated 2% Net Smelter Return (NSR) royalty on two mineral claims within the Shea Creek Joint Venture, part of a 16-uranium-royalty portfolio expected to be acquired through its pending transaction with Royal Uranium Inc. The Shea Creek project hosts significant undeveloped uranium resources in Can…